Empagliflozin's cardiovascular benefit holds across patient subgroups, study finds

A real-world analysis of 2014-2020 Medicare claims data compared empagliflozin to DPP-4 inhibitors and GLP-1 receptor agonists in adults aged 65 and older with type 2 diabetes. The study reported that empagliflozin was associated with lower rates of major adverse cardiovascular events, heart failure hospitalization, and all-cause mortality versus DPP-4 inhibitors, and lower heart failure hospitalization versus GLP-1 receptor agonists, with no effect heterogeneity by sociodemographic factors but greater absolute benefit reported in patients with prevalent cardiovascular disease.

Most relevant for: Older adults with type 2 diabetes, particularly those with pre-existing cardiovascular disease, being considered for glucose-lowering therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.